The broad societal value of pembrolizumab for women’s cancer in Canada

20260 citationsJournal Article

Authors

Elizabeth Brook · Instituto Nacional de Medicina Tropical

K. Patterson

Nishini Wijenayake

Matthew Madin-Warburton

Kathryn Mishkin · Merck & Co., Inc., Rahway, NJ, USA (United States)

Marie-Claude Meilleur · Merck Canada Inc. (Canada)

Annabelle Davies · MSD (UK) Limited (United Kingdom)

Kate Young · Merck & Co., Inc., Rahway, NJ, USA (United States)

Abstract

Broadening the perspective to include additional value elements considerably increased the overall value of treatment of women's cancer compared with the TPP, indicating that the perspective used by health technology bodies may not fully capture the societal value of therapeutics.

Topics & Keywords

Health Systems, Economic Evaluations, Quality of Life Economic and Financial Impacts of Cancer Sex and Gender in Healthcare

UN Sustainable Development Goals

Gender equality

Publication Details

Published in: Future Oncology

Volume 22, Issue 8, pp. 939-952

DOI: 10.1080/14796694.2026.2639738

Field-Weighted Citation Impact: 0.00